Similarly, VCAM-1-targeted scFv was used in a study, to deliver microRNA-126 directly to the inflamed endothelial cells in the aorta, providing a targeted therapeutic approach to prevent the progression of AAA (98). The gene discussed is VCAM1; the disease is triple-A syndrome.